Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Rheumatoid Arthritis (US) 2018

Product Code:
Publication Date:
November 2018

What are the market access obstacles that are shaping the US rheumatoid arthritis market and which brands are winning out?

  • How are market barriers affecting rheumatoid arthritis drug prescribing?
  • How do market barriers affect the market share of leading brands?
  • What specific market access barriers are challenging each brand?
  • Which brands gain and lose the most market share due to market barriers?

High cost, no formulary listing and stock availability are just some of the barriers that can negatively influence prescribing volumes and exert downward pressure on profitability.  What market access barriers are influencing physicians’ therapy choices and how is this determining market share?

This and other key questions are answered in this insightful November 2018 analysis of 12 leading rheumatoid arthritis (RA) brands. Based on the results of an in-depth survey of 100 US-based rheumatologists, Market Access Impact (US): Rheumatoid Arthritis identifies the market access barriers that are shaping the competitive landscape for leading rheumatoid arthritis brands in the US and provides clear pointers for management action.

Buy Now

Buy and Download this report

Evaluating leading companies in the US rheumatoid arthritis sector

  • Abbvie
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Janssen Biotech
  • Pfizer
  • Roche
  • Roche/Biogen
  • Sanofi/Regeneron
  • UCB

Leading brands covered in this report

  • Actemra (tocilizumab; Roche)
  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Amgen)
  • Humira (adalimumab; Abbvie)
  • Inflectra (infliximab; Pfizer)
  • Kevzara (sarilumab; Sanofi/Regeneron)
  • Olumiant (baricitinib; Eli Lilly)
  • Orencia (abatacept; Bristol-Myers Squibb)
  • Remicade (infliximab; Janssen Biotech)
  • Rituxan (rituximab; Roche/Biogen)
  • Simponi (golimumab; Janssen Biotech)
  • Xeljanz (tofacitinib; Pfizer)

Answering important market access questions

  • What underpins the physicians’ prescribing of Humira, Enbrel and Remicade?
  • What is the overall impact of market barriers on prescribing?
  • Not available on formulary? Not recommended in guidelines? Limited availability? What market access obstacles are impacting Rituxan, Simponi and Xeljanz?
  • How many market barriers are impacting Kevzara, Rituxan and Xeljanz?
  • How are market access issues impacting the market shares of Actemra, Cimzia and Enbrel and which competitor brands are benefitting?

Market access barriers examined in this survey

  • Not available on formulary
  • Too expensive
  • Not recommended by guidelines
  • Limited availability
  • Patients prefer other medications
  • Only recommended for certain patient types
  • Is not reimbursable

Exclusive to FirstView, Market Access Impact surveys reveal the barriers that influence prescribing, identify the brands that win or lose market share, and highlight the
brand-specific market access challenges that management must overcome

The experience of the physicians surveyed

This detailed analysis is based on a survey of 100 US rheumatologists with a wealth of experience treating rheumatoid arthritis. On average they:

  • Saw 104 patients the month preceding the survey
  • Have 18 years in practice
  • Have prescribed at least one of the brands assessed

This report gives you...

  • Practical data to understand how market barriers impact the prescribing decisions rheumatologists treating rheumatoid arthritis make
  • 31 clear, easy-to-read, charts that provide at-a-glance understanding of the survey findings
  • Actionable and detailed information identifying specific areas where medical access teams can improve brand share

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other RHEUMATOID ARTHRITIS reports available

Market Access Impact (Europe): Rheumatoid Arthritis

Medical Affairs Reputations (US): Rheumatoid Arthritis

Medical Affairs Reputations (EU5): Rheumatoid Arthritis

NPS+ US: Rheumatoid Arthritis

NPS+ Europe: Rheumatoid Arthritis 

KOL Insights: Rheumatoid Arthritis

To learn about our cost effective Rheumatoid Arthritis intelligence package of all reports, please contact us at info@fwreports.com


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved